Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Read More…
Industry, Sector and Symbol
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Phone225-292-2031
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.96 billion
Profitability
Miscellaneous
Employees21,300
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable
Amedisys (NASDAQ:AMED) Frequently Asked Questions
What is Amedisys' stock symbol?
Amedisys trades on the NASDAQ under the ticker symbol "AMED."
How were Amedisys' earnings last quarter?
Amedisys Inc (NASDAQ:AMED) posted its quarterly earnings data on Tuesday, February, 18th. The health services provider reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.01. The health services provider earned $500.70 million during the quarter, compared to analysts' expectations of $511.58 million. Amedisys had a net margin of 6.49% and a return on equity of 24.95%. Amedisys's revenue was up 15.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.91 EPS. View Amedisys' Earnings History.
When is Amedisys' next earnings date?
What guidance has Amedisys issued on next quarter's earnings?
Amedisys updated its FY20 earnings guidance on Tuesday, February, 18th. The company provided earnings per share (EPS) guidance of $4.90-5.13 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.91. The company issued revenue guidance of $2.115-2.160 billion, compared to the consensus revenue estimate of $2.12 billion.
What price target have analysts set for AMED?
13 brokerages have issued 12 month price objectives for Amedisys' stock. Their forecasts range from $124.00 to $225.00. On average, they expect Amedisys' share price to reach $177.07 in the next twelve months. This suggests that the stock has a possible downside of 7.6%. View Analyst Price Targets for Amedisys.
What is the consensus analysts' recommendation for Amedisys?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amedisys.
Has Amedisys been receiving favorable news coverage?
Press coverage about AMED stock has trended somewhat negative this week, according to InfoTrie. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amedisys earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the health services provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Amedisys.
Are investors shorting Amedisys?
Amedisys saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,180,000 shares, a decline of 7.8% from the January 15th total of 1,280,000 shares. Based on an average daily trading volume, of 235,400 shares, the days-to-cover ratio is presently 5.0 days. Approximately 3.7% of the company's stock are short sold. View Amedisys' Current Options Chain.
Who are some of Amedisys' key competitors?
Some companies that are related to Amedisys include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), BioScrip (BIOS), Davita (DVA), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), R1 RCM (RCM), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).
What other stocks do shareholders of Amedisys own?
Who are Amedisys' key executives?
Amedisys' management team includes the folowing people:
- Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 58)
- Mr. Scott G. Ginn, Chief Financial Officer (Age 50)
- Mr. Christopher T. Gerard, Chief Operating Officer (Age 52)
- Mr. David L. Kemmerly, Sr. VP of Gov. Affairs & Gen. Counsel (Age 56)
- Ms. Sharon Brunecz, Chief HR Officer (Age 52)
Who are Amedisys' major shareholders?
Amedisys' stock is owned by a number of of institutional and retail investors. Top institutional investors include William Blair Investment Management LLC (3.32%), State Street Corp (3.12%), Alliancebernstein L.P. (2.17%), Riverbridge Partners LLC (2.06%), Geode Capital Management LLC (1.46%) and Bank of America Corp DE (1.35%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Kkr Credit Advisors (Us) Llc, Linda J Hall, Michael Paul North, Scott G Ginn and Sharon Brunecz. View Institutional Ownership Trends for Amedisys.
Which major investors are selling Amedisys stock?
AMED stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Bank of New York Mellon Corp, AQR Capital Management LLC, FMR LLC, Marshall Wace LLP, Rothschild & Co. Asset Management US Inc., Marshall Wace North America L.P. and Man Group plc. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn and Sharon Brunecz. View Insider Buying and Selling for Amedisys.
Which major investors are buying Amedisys stock?
AMED stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Castleark Management LLC, William Blair Investment Management LLC, British Airways Pensions Investment Management Ltd, Columbus Circle Investors, Renaissance Technologies LLC, AXA and Great Lakes Advisors LLC. View Insider Buying and Selling for Amedisys.
How do I buy shares of Amedisys?
Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Amedisys' stock price today?
One share of AMED stock can currently be purchased for approximately $191.62.
How big of a company is Amedisys?
Amedisys has a market capitalization of $6.19 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,300 workers across the globe.View Additional Information About Amedisys.
What is Amedisys' official website?
How can I contact Amedisys?
Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]
MarketBeat Community Rating for Amedisys (NASDAQ AMED)
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe AMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
